Updates on billiary track cancer - a role for durvalumab?
And pemigatinib - an approval in r/r myeloid/lymphoid neoplasms.
Plus, an oral suspension of ibrutinib is approved and more evidence ICI combination should be given early in BRAF-mutated metastatic melanoma (rather than waiting until disease progression on TKIs)
